Thermo Fisher Q2 2026: Revenue Reaches $11.99B, Clario Deal Closes, Microbiology Unit Sold
TMO sits 30% above its 52-week low of $435.27 on light trading volume (0.2× avg).
Summary
Thermo Fisher's Q2 2026 10-Q reports revenue of $11.99B (+10% YoY) and adjusted EPS of $6.03 (+13% YoY), alongside the closing of the $9.1B Clario acquisition and the planned $1.075B sale of its microbiology business.
Key Events · Earnings and Guidance · TMO
-
Q2 Revenue and Earnings Beat
Revenue reached $11.99B, up 10% year-over-year, with organic growth of 5%. Adjusted EPS climbed 13% to $6.03, driven by robust demand in pharma/biotech and industrial end markets.
-
Clario Acquisition Closed
The $9.1B acquisition of Clario Holdings was completed on March 24, 2026, adding endpoint data solutions for clinical trials to the Laboratory Products and Biopharma Services segment.
-
Microbiology Business Divestiture
An agreement was reached to sell the microbiology business to Astorg for $1.075B, consisting of cash and a $50M seller note; the transaction is expected to close in Q3 2026.
-
Restructuring Program Underway
Restructuring actions have been identified that are expected to result in additional charges of approximately $220M, primarily in 2026, focused on the Laboratory Products and Biopharma Services segment.
Analysis · TMO · Industrial Applications And Services
A strong Q2 saw Thermo Fisher deliver 10% revenue growth and a 13% rise in adjusted EPS, fueled by broad-based demand across pharma, biotech, and industrial end markets. The period also marked the completion of the $9.1B Clario acquisition, which bolsters clinical research capabilities, and the announcement of a $1.075B divestiture of the microbiology business. Management is pressing ahead with a significant restructuring program expected to incur $220M in additional charges, while returning $4.0B to shareholders through buybacks in the first half. The results confirm the strengthening customer activity flagged in the July 23 pre-release, but the 10-Q adds granularity on segment performance, capital allocation, and the strategic reshaping of the portfolio.
At the time of this filing, TMO was trading at $564.80 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $209.9B. The 52-week trading range was $435.27 to $643.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.